Product Details

Uniprot No.

P56279

Target Names

TCL1A

Alternative Names

T-cell leukemia/lymphoma protein 1A (Oncogene TCL-1) (Oncogene TCL1) (Protein p14 TCL1), TCL1A, TCL1

Species Reactivity

Human

Immunogen

A synthesized peptide from human TCL1A protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

9B8

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC, FC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

TCL1A serves as a critical oncogene in lymphoid malignancies, functioning as a coactivator of AKT kinase signaling pathways that promote cell survival and proliferation. This protein is particularly significant in the study of T-cell prolymphocytic leukemia and certain B-cell malignancies, where its aberrant expression contributes to disease pathogenesis. Researchers investigating lymphoid development, leukemogenesis, and AKT-mediated signaling pathways will find TCL1A an essential target for understanding these biological processes.

This recombinant monoclonal antibody, clone 9B8, offers the reproducibility and consistency that demanding research applications require. Because it is produced from a defined sequence in a controlled expression system, you can expect uniform performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations. The rabbit host and monoclonal nature combine high affinity binding with exceptional specificity for human TCL1A.

Validation studies demonstrate this antibody's versatility across multiple experimental platforms. Immunohistochemistry testing in paraffin-embedded human glioma tissue shows clear staining at 1:100 dilution using citrate buffer antigen retrieval, confirming its utility for examining TCL1A expression patterns in fixed tissue specimens. Flow cytometry analysis using Jurkat cells, a T-cell leukemia line with established TCL1A expression, reveals distinct positive signal separation from isotype control at 1:100 dilution following fixation and permeabilization, supporting intracellular detection workflows.

This antibody is well-suited for researchers exploring TCL1A's role in hematological malignancies, T-cell biology, and oncogenic signaling networks, providing a reliable tool for both discovery research and translational studies.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival.

Gene References into Functions

Combination of T-cell lymphoma-1 protein (TCL1)-overexpression and damaging ataxia telangiectasia mutated protein (ATM) functionally synergistically contribute to T-cell prolymphocytic leukemia (T-PLL) specific phenotype of impaired DNA damage processing. PMID: 29449575
Case Report: hematogones can express TCL-1 in patients with T-cell prolymphocytic leukemia after therapy. PMID: 28232160
TCL1A is not only a useful biomarker for prognostic evaluation in stage II/III colorectal cancer patients. PMID: 28178623
Our results suggest that intratumoral TCL1A+ B cells are important for controlling cervical cancer development. PMID: 26299617
Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in patient with MCL and call for prospective studies. PMID: 25688912
We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenstrom macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact. PMID: 26493619
Suggest miR-181b as therapeutic target for chronic lymphocytic leukemia in the Emicro-TCL1 mouse model. PMID: 26090867
High TCL1A expression is associated with chronic lymphocytic leukemia. PMID: 25936528
Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population PMID: 25481307
Peptide-based TCL1-interphase mimics were potent in steric AKT antagonization. PMID: 25348018
demonstrated that miR-3676 targets three consecutive 28-bp repeats within 3'UTR of TCL1 and showed that miR-3676 is a powerful inhibitor of TCL1 PMID: 25646413
Case Report: T-cell lymphoblastic leukemia/lymphoma with t(7;14)(p15;q32) [TCRgamma-TCL1A translocation] confirmed by FISH. PMID: 24966976
Report frequent TCL1A rearrangements in T-cell prolymphocytic leukemia with cutaneous involvement. PMID: 25310835
TCL1-Tg:p53(-/-) leukemia cells exhibit higher survival capacity and are more drug resistant than the leukemia cells from TCL1-Tg:p53wt mice PMID: 23608884
TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q. PMID: 22875623
SNPs near the 3' terminus of TCL1A were associated with aromatase inhibitors-dependent musculoskeletal pain. Estradiol induced SNP-dependent TCL1A expression. PMID: 22405131
Data indicate that up-regulated transcription of TCL1A was observed in two cases. PMID: 22553924
Our findings reveal a functional interaction between Tcl1 and Hsp70 and identify Tcl1 as a novel Hsp70 client protein PMID: 23160471
Intracellular expression of the TCL1 as well as membrane and intracellular expression of ILT7 in plasmacytoid dendritic cell leukemia (pDCL) samples and 61 non-pDC acute leukemia samples, were tested. PMID: 22674796
These findings demonstrate that the microenvironment has a proactive role in the regulation of the known signaling enhancer and pro-survival molecule TCL1 in CLL. PMID: 22460735
TCL1 is hyperexpressed in multiple B-cell lymphomas. PMID: 22645177
100% of dysgerminomas were positive for TCL1, but all immature teratomas were negative. PMID: 22448662
genetic association studies in a Japanese population: Data suggest that a substantial number of patients with T-cell prolymphocytic leukemia exhibit abnormal expression of TCL1A probably due to rearrangement in region of TCL1 gene. PMID: 22189846
CLL samples with high Tcl1 expression showed a decrease in DNA methylation compared with CLL samples with low Tcl1 expression PMID: 22308499
Using primary chronic lymphocytic leukemia cells we have shown an inverse relationship between TCL1 and PTPROt expression. PMID: 22001392
Data indicate an inverse correlation between miR-16-1, miR-181a, miR-181b, and level of expression of TCL-1 and BCL-2, which suggest that these miRNAs may implicate in negatively regulating target mRNA at transcriptional level. PMID: 21130495
This study identified 4 single nucleotide polymorphisms related to TCL1A that, when present, were associated with musculoskeletal adverse effects to anastrozole or exemestane treatment in postmenopausal women with stage I to III breast cancer. PMID: 21172079
TCL1 is a diagnostic marker for intratubular germ cell neoplasia and classic seminoma. PMID: 20553335
TCL1 positivity was predominantly found in germinal center phenotype diffuse large B-cell lymphoma. PMID: 20382409
CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. PMID: 20357824
Immunohistochemical evaluation of TCL1 expression may be useful for substantiating a diagnosis of unclassified type of intratubular germ cell neoplasia or seminoma. PMID: 20395523
TCL1 mRNA expression may predict clinical outcome in CLL and that the IGHV3-21 subset, regardless of mutational status, displays high TCL1 expression. PMID: 19889012
establish that the association between TCL1A and IkappaB is compatible with AKT binding to TCL1A, but incompatible with IkappaB binding to NF-kappaB PMID: 19668332
An exposed hydrophobic patch composed of two discontinuous amino acid stretches has been identified near one end of the TCL1 beta-barrel that is required for TCL1-AKT binding association. PMID: 12009899
Increased TCL1 expression correlates with PBC-ALL progression and loss of TEL expression. TCL1 expression is important for the maturation of precursor lymphocytes but not differentiated B or T cells. PMID: 12127395
data demonstrate that TCL1 is a powerful oncogene that, when overexpressed in both B and T cells, predominantly yields mature B cell lymphomas PMID: 12381789
oncogene transactivation by Sp1 PMID: 12421830
results further support derivation of blastic tumors of skin from dendritic cells and demonstrate TCL1 proto-oncogene protein expression in this tumor PMID: 12576313
altered expression in Burkitt lymphomas in the presence of Epstein-Barr virus PMID: 12672960
Involved in the pathogenesis of mature leukemias and lymphomas: mature T-cell leukemia and chronic lymphocytic leukemia(review) PMID: 15325703
Akt kinase activity can be inhibited by a peptide spanning the betaA strand of the proto-oncogene TCL1 PMID: 15459205
Detailed mechanism for TCL1-augmented signaling helps explain the delayed occurrence of mature T cell expansions and leukemias despite tumorigenic TCL1 dysregulation that begins in early thymocytes. PMID: 16002684
In EBV-negative diffuse large B-cell lymphoma and Burkitt lymphoma-derived cell lines infected in vitro with a recombinant EBV, high expression of EBNA2 inversely correlated with expression of germinal center-associated genes, BCL6 and TCL1. PMID: 17151114
Expression levels of microRNA generally inversely correlated with Tcl1 expression in chronic lymphocytic leukemia. PMID: 17178851
Biological action of the proto-oncogene TCL1 family and the development avenues for a suppressive drug specific for Akt, a core intracellular survival regulator.[REVIEW] PMID: 17360849
TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. PMID: 17548807
TCL1 expression in B-cell tumors parallels its regulation in non-neoplastic B cells and can be used diagnostically as an indicator of the differentiation stage of a given B-cell tumor. PMID: 17592280
TCL1A deregulation may be caused by faulty gene silencing as a potential consequence of losses of 7q miRNAs in splenic marginal zone lymphoma. PMID: 17625607
Lower TCL-1 levels were associated with improved complete remission rate and progression-free survival PMID: 17659340
TCL1 inhibits activation-induced cell death in T cells by blocking PKCtheta and ERK activation, upon cellular activation PMID: 17846228

Hide All

Involvement in disease

Chromosomal aberrations activating TCL1A are found in chronic T-cell leukemias (T-CLL). Translocation t(14;14)(q11;q32); translocation t(7;14)(q35;q32); inversion inv(14)(q11;q32) that involves the T-cell receptor alpha/delta loci.

Subcellular Location

Cytoplasm. Nucleus. Microsome. Endoplasmic reticulum. Note=Microsomal fraction.

Protein Families

TCL1 family

Tissue Specificity

Restricted in the T-cell lineage to immature thymocytes and activated peripheral lymphocytes. Preferentially expressed early in T- and B-lymphocyte differentiation.

Database Links

HGNC: 11648

OMIM: 186960

KEGG: hsa:8115

STRING: 9606.ENSP00000385036

UniGene: Hs.2484

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA198357A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA198357A0HU diluted at 1:100 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Overlay Peak curve showing jurkat cells stained with CSB-RA198357A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

TCL1A Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background